A Meta-Analysis of Efficacy and Safety Data from Head-to-Head First-Line Trials of Epidermal Growth Factor Receptor Inhibitors versus Bevacizumab in Adult Patients with RAS Wild-Type Metastatic Colorectal Cancer by Sidedness

The first-line treatment choice of EGFRIs plus doublet chemotherapy vs. bevacizumab plus doublet chemotherapy remains a topic of interest for patients with left-sided RAS WT mCRC. We conducted a systematic literature review and meta-analysis of clinical trial data published between 2015 and 2024. We evaluated the relative efficacy and safety of first-line EGFRIs plus doublet chemotherapy (FOLFIRI or FOLFOX) vs. bevacizumab plus doublet chemotherapy for patients with RAS WT left-sided mCRC, as well as in all- and right-sided tumors.

Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Takayuki Yoshino, Naushin Hooda, Diana Younan, Kei Muro, Kohei Shitara, Volker Heinemann, Bert Howard O ’neil, Fernando Rivera Herrero, Marc Peeters, Junpei Soeda, Mina Suh, Heidi Reichert, Khalid Mezzi, Jon Fryzek, Victoria Chia, Marko Rehn, Sebastian Tags: Review Source Type: research